HMGB1 in TME (tumor microenvironment)

HMGB1 in TME (tumor microenvironment)


HMGB1 is a multifunctional protein. It has dual roles in tumor microenvironment (TME). During tumor development, HMGB1 acts as a pro-tumoral protein by promoting tumor growth, angiogenesis, immunosuppression, invasion and metastasis. However, HMGB1 also plays an anti-tumoral role by mediating immunogenic cell death (ICD) during chemoradiotherapy and enhance anti-tumor immunity. HMGB1 provides potentially therapeutic strategy for cancer chemoradiotherapy and immunotherapy.




● HMGB1 induces angiogenesis

Endothelial cells (ECs) play pivotal roles in tumor angiogenesis. Tumor-derived HMGB1 stimulates the migratory and sprouting capacity of ECs. Besides, HMGB1 also recruits and activate macrophages to produce angiogenic factors for vasculature formation.

   Microvascular Density Antibody Panel (ARG30327)
   Angiogenesis Antibody Panel (ARG30328)



● Immunosuppressive role of HMGB1

In tumor microenvironment (TME), tumor-derived HMGB1 suppresses CD8+ T cell-dependent antitumor immunity by facilitating myeloid-derived suppressor cell (MDSC) differentiation and stimulating Treg-mediated immunosuppression. Moreover, HMGB1 binds to immunosuppressive receptor TIM‐3 on dendritic cells (DCs), interferes DC’s function and therefore inhibits the anti-tumor immune response.

   Human MDSC Marker Antibody Duo (ARG30336)
   Mouse MDSC Marker Antibody Duo (ARG30335)
   Regulatory T Cell Marker Antibody Duo (ARG30086)



● HMGB1 promotes invasion and metastasis

HMGB1 is highly expressed in a variety of malignant tumors. It promotes epithelial-mesenchymal transition (EMT), invasion and metastasis by HMGB1-RAGE signaling.

   EMT Marker Antibody Duo (ARG30320)



● HMGB1 activate immunogenic cell death (ICD)

ICD is a form of cell death resulting in an activation of immune response. ICD is triggered by damage-associated molecular patterns (DAMPs) which include HMGB1 release. The dying cell-derived HMGB1 binds to TLR4 to induce DC maturation, antigen presentation and subsequent cytotoxicity mediated by CD8+ T cells. Monitoring HMGB1 release is common for evaluating the effects of chemoradiotherapy or ICD.

arigo offers a total solution, including protein, neutralizing antibodies, and ELISA kits, to facilitate the research of HMGB1.